Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/123357
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAriza Sáenz, Martha Rocío-
dc.contributor.authorEspina García, Marta-
dc.contributor.authorBolaños, Núria-
dc.contributor.authorCalpena Campmany, Ana Cristina-
dc.contributor.authorGomara, Maria José-
dc.contributor.authorHaro, Isabel-
dc.contributor.authorGarcía López, María Luisa-
dc.date.accessioned2018-07-04T13:17:50Z-
dc.date.available2018-12-31T06:10:25Z-
dc.date.issued2017-11-
dc.identifier.issn0939-6411-
dc.identifier.urihttp://hdl.handle.net/2445/123357-
dc.description.abstractDespite the great effort to decrease the HIV infectivity rate, current antiretroviral therapy has several weaknesses; poor bioavailability, development of drug resistance and poor ability to access tissues. However, molecules such as peptides have emerged as a new expectative to HIV eradication. The vaginal mucosa is the main spreading point of HIV. There are natural barriers such as the vaginal fluid which protects the vaginal epithelium from any foreign agents reaching it. This work has developed and characterized Nanoparticles (NPs) coated with glycol chitosan (GC), loaded with an HIV-1 inhibitor peptide (E2). In vitro release and ex vivo studies were carried out using the vaginal mucosa of swine and the peptide was determined by HPLC MS/MS validated method. Moreover, the peptide was labeled with 5(6)-carboxyfluoresceine and entrapped into the NPs to carried out in vivo studies and to evaluate the NPs penetration and toxicity in the vaginal mucosa of the swine. The mean size of the NPs, ξ and the loading percentage were fundamental features for to reach the vaginal tissue and to release the peptide within intercellular space. The obtained results suggesting that the fusion inhibitor peptides loaded into the NPs coated with GC might be a new way to fight the HIV-1, due to the formulation might reach the human epithelial mucosa and release peptide without any side effects.-
dc.format.extent28 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherElsevier B.V.-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.ejpb.2017.08.008-
dc.relation.ispartofEuropean Journal of Pharmaceutics and Biopharmaceutics, 2017, vol. 120, p. 98-106-
dc.relation.urihttps://doi.org/10.1016/j.ejpb.2017.08.008-
dc.rightscc-by-nc-nd (c) Elsevier B.V., 2017-
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es-
dc.sourceArticles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)-
dc.subject.classificationNanopartícules-
dc.subject.classificationPèptids-
dc.subject.classificationSistemes d'alliberament de medicaments-
dc.subject.classificationVagina-
dc.subject.classificationMembrana mucosa-
dc.subject.otherNanoparticles-
dc.subject.otherPeptides-
dc.subject.otherDrug delivery systems-
dc.subject.otherVagina-
dc.subject.otherMucous membrane-
dc.titlePenetration of polymeric nanoparticles loaded with an HIV-1 inhibitor peptide derived from GB virus C in a vaginal mucosa model-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec673740-
dc.date.updated2018-07-04T13:17:51Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid28842284-
Appears in Collections:Articles publicats en revistes (Medicina)
Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)

Files in This Item:
File Description SizeFormat 
673740.pdf19 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons